The Institute of Cancer Research, London, UK
The Institute of Cancer Research, London, UK.
BMJ Open. 2024 Jan 24;14(1):e075755. doi: 10.1136/bmjopen-2023-075755.
The urgency of the climate crisis requires attention from biomedical research, not least clinical trials which can involve significant greenhouse gas emissions. The Low Carbon Clinical Trials Working Group set out a strategy to reduce the emissions of clinical trials, starting with the development of a method to measure their carbon footprint (COe).
As a first step, we developed a process map defining clinical trial core activities. Corresponding emission factors were sourced to convert activity data into greenhouse gas emissions. The subsequent method was applied to two Cancer Research UK (CRUK)-funded trials (the international randomised sarcoma trial CASPS (ISRCTN63733470) and the UK cohort-based breast cancer trial PRIMETIME (ISRCTN41579286)). A guidance document defining the scope, method and assumptions was written to allow application to any publicly funded/investigator initiated clinical trial.
Trial specific activities over and above routine care were grouped into 10 modules covering trial set up, conduct and closure. We identified emission factors for all trial activities within both trials and used them to estimate their total carbon footprint. The carbon footprint of CASPS, an international phase 2 trial of an investigational medicinal product with 47 participants, was 72 tonnes COe, largely attributable to clinical trials unit emissions and staff travel. PRIMETIME, a UK-based phase 3 non-investigational medicinal product trial with 1962 patients, produced 89 tonnes COe, largely attributable to trial-specific in-person participant assessments.
We have developed a method and guidance that trialists can use to determine the carbon footprint of clinical trials. The guidance can be used to identify carbon hotspots where alternative approaches to trial design and conduct could reduce a trial footprint, and where methodology research is required to investigate the potential impact of interventions taken to reduce carbon emissions. We will continue to refine the guidance to increase the potential application and improve usability.
气候危机的紧迫性要求生物医学研究予以关注,尤其是临床试验,因为它们可能会产生大量温室气体排放。低碳临床试验工作组提出了一项策略,以减少临床试验的排放量,首先是开发一种衡量临床试验碳足迹(COe)的方法。
作为第一步,我们制定了一个流程图,定义了临床试验的核心活动。我们从源头获取相应的排放因子,将活动数据转换为温室气体排放。然后将该方法应用于两项由英国癌症研究中心(CRUK)资助的试验(国际随机肉瘤试验 CASPS(ISRCTN63733470)和基于英国队列的乳腺癌试验 PRIMETIME(ISRCTN41579286))。我们编写了一份指南文件,定义了范围、方法和假设,以允许将其应用于任何由公共资金资助/由研究者发起的临床试验。
试验中超出常规护理的特定活动被分为 10 个模块,涵盖试验启动、进行和关闭。我们确定了两个试验中所有试验活动的排放因子,并使用它们来估算其总碳足迹。CASPS 是一项针对研究性药物的国际 2 期试验,涉及 47 名参与者,其碳足迹为 72 公吨 COe,主要归因于临床试验单位的排放和员工旅行。PRIMETIME 是一项基于英国的 3 期非研究性药物试验,涉及 1962 名患者,产生了 89 公吨 COe,主要归因于试验特异性的面对面参与者评估。
我们已经开发了一种方法和指南,供试验人员用于确定临床试验的碳足迹。该指南可用于确定碳热点,即试验设计和进行的替代方法可以减少试验足迹的地方,以及需要进行方法学研究的地方,以调查为减少碳排放而采取的干预措施的潜在影响。我们将继续完善该指南,以增加潜在的应用和提高可用性。